New Therapies in Development for Multiple Myeloma

A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.